LONDON: AstraZeneca could pay up to US$6 billion to Japan’s Daiichi Sankyo to develop and market a type of targeted cancer treatment in the second multi-billion dollar cancer drug collaboration between the two companies.
The drugmakers signed a near US$7 billion deal last year for a breast cancer treatment, now called Enhertu, which is being tested in other tumour types too.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: